Plasma fibrinogen regularly extravasates and is clotted to crosslinked fibrin in the extravascular space in a wide variety of solid human and animal tumors, both autochthonous and transplantable. Tumor fibrin deposits are also degraded at a rapid rate. These fibrin deposits, and their degradation products, are likely to have significance for tumor growth. In experimental animals, fibrin gels alone induce angiogenesis in the absence of tumor cells, and fibrinogen/fibrin degradation products possess a variety of significant biological activities. Fibrin is also deposited in wounds where its degradation with healing accompanies angiogenesis and collagenous stroma formation. These studies suggest that tumors may behave in the body like wounds and, in fact, may induce new blood vessels and mature tumor stroma by activating the host's wound healing response. A multidisciplinary approach will be used to investigate this hypothesis. Accumulation and turnover of fibrinogen/fibrin will be compared in solid tumors, in defined skin wounds, and in ascites tumors where malignant cells grow in suspension without constraints imposed by connective tissue stroma. Fibrinogen/fibrin catabolites generated in tumors and wounds in vivo will be detected and compared either by following the fate of intravenously injected 125 I-fibrinogen or by immunoreactivity. In either case, tumor and wound extracts or ascites fluids will be subjected to SDS-PAGE or other electrophoretic steps (followed by autoradiography or immunoblotting), HPLC, etc. We will also define the sites, cells, and proteases responsible for fibrinogen/fibrin catabolite generation Agents that modulate clotting and fibrinolysis will be tested for their capacity to alter tumor growth rate, growth pattern (extent of desmoplasia), and metastases. Finally, fibrinogen extravasation and fibrin accumulation and turnover will be quantitated and compared in tumors other than transplantable carcinomas; e.g., sarcomas, lymphomas, melanomas, and metastases. Together, these experiments will shed new light on the pathogenesis of angiogenesis and tumor stroma formation. They may also elucidate mechanisms that determine the distinctly different growth patterns assumed by the same tumor cell lines when these grow in ascites or solid form.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA028471-09
Application #
3168148
Study Section
Metabolic Pathology Study Section (MEP)
Project Start
1980-02-01
Project End
1993-01-31
Budget Start
1988-02-01
Budget End
1989-01-31
Support Year
9
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02215
Lin, K; Nagy, J A; Xu, H et al. (1994) Compartmental distribution of tumor-specific monoclonal antibodies in human melanoma xenografts. Cancer Res 54:2269-77
Nagy, J A; Herzberg, K T; Dvorak, J M et al. (1993) Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. Cancer Res 53:2631-43
Brown, L F; Dubin, D; Lavigne, L et al. (1993) Macrophages and fibroblasts express embryonic fibronectins during cutaneous wound healing. Am J Pathol 142:793-801
Sioussat, T M; Dvorak, H F; Brock, T A et al. (1993) Inhibition of vascular permeability factor (vascular endothelial growth factor) with antipeptide antibodies. Arch Biochem Biophys 301:15-20
Brown, L F; Lanir, N; McDonagh, J et al. (1993) Fibroblast migration in fibrin gel matrices. Am J Pathol 142:273-83
Shockley, T R; Lin, K; Sung, C et al. (1992) A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels. Cancer Res 52:357-66
Brown, L F; Berse, B; Van de Water, L et al. (1992) Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell 3:1169-80
Yeo, K T; Sioussat, T M; Faix, J D et al. (1992) Development of time-resolved immunofluorometric assay of vascular permeability factor. Clin Chem 38:71-5
Dvorak, H F; Nagy, J A; Berse, B et al. (1992) Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann N Y Acad Sci 667:101-11
Berse, B; Brown, L F; Van de Water, L et al. (1992) Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 3:211-20

Showing the most recent 10 out of 36 publications